Once-Daily Azithromycin for 3 Days Compared with Clarithromycin for 10 Days for Acute Exacerbation of Chronic Bronchitis
- First Online:
To compare the efficacy and safety of oral azithromycin 500mg once daily for 3 days with those of oral clarithromycin 500mg twice daily for 10 days.
Randomized, double-blind, double-dummy, multicenter study.
Seventy-six study centers in eight countries (Argentina, Brazil, Canada, Chile, Costa Rica, India, South Africa, and USA).
Three hundred and twenty-two adult outpatients with acute exacerbation of chronic bronchitis (AECB) as documented by increased cough or sputum production, worsening dyspnea, and purulent sputum production.
Randomization 1: 1 to azithromycin 500mg once daily for 3 days or clarithromycin 500mg twice daily for 10 days.
The primary efficacy endpoint was clinical response at day 21–24, or test of cure (TOC) visit in the modified intent-to-treat (MITT) analysis (n = 318 patients). The TOC clinical cure rates in the MITT population were equivalent in the two treatment groups at 85% with azithromycin and 82% with clarithromycin (95% CI–5.9%, 12.0%). Clinical success rates on day 10–12 were also equivalent at 93% with azithromycin and 94% with clarithromycin (95% CI–7.9%, 4.4%). Clinical cure rates at TOC by pathogen were equivalent for the two treatment groups for Haemophilus influenzae (azithromycin, 85.7%; clarithromycin, 87.5%), Moraxella catarrhalis (91.7% and 80.0%, respectively) and Streptococcus pneumoniae (90.6% and 77.8%, respectively). Bacteriologic success rates were also equivalent between the azithromycin and clarithromycin treatment groups at TOC for S. pneumoniae (90.6% and 85.2%, respectively), H. influenzae (71.4% and 81.3%, respectively) and M. catarrhalis (100% and 86.7%, respectively). The overall incidence of treatment-related adverse events was similar in the azithromycin and clarithromycin groups (20.9% and 26.8%, respectively), with the most common being abdominal pain (6.3% and 6.1%, respectively), diarrhea (4.4% and 5.5%, respectively), and nausea (4.4% and 3.7%, respectively).
Three-day treatment with azithromycin 500mg once daily is equivalent to a 10-day treatment with clarithromycin 500mg twice daily in adult patients with AECB.
- 2.Pauwels RA, Buist AS, Calverley PMA, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163: 1256–76PubMedGoogle Scholar
- 3.Celli BR. Chronic obstructive pulmonary disease. In: Khan MG, Lynch JP, editors. Pulmonary disease diagnosis and therapy. Baltimore (MD): Williams and Wilkins, 1997: 199–236Google Scholar
- 4.World Health Organization. The World Health Report 1999: making a difference. Geneva: World Health Organization, 1999; 1: 2Google Scholar
- 5.Deaths/mortality US 1998. Hyattsville (MD): National Center for Health Statistics, 1998Google Scholar
- 6.American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152 (5 Pt 2 Suppl.): 77–121Google Scholar
- 7.Balter MS, Hyland RH, Low D, et al. Recommendations on the management of chronic bronchitis: a practical guide for Canadian physicians. CMAJ 1994; 10 Suppl.: 5–23Google Scholar
- 11.Gotfried MH. Diagnosis and management of acute exacerbation of chronic bronchitis. Hosp Med 1997; 33 Suppl.: 2–4Google Scholar
- 13.Reynolds HY. Chronic bronchitis and acute infectious exacerbations. In: Mandell GL, Bennett JE, Dollin R, editors. X: principles and practices of infectious diseases. 4th ed. New York: Churchill Livingstone, 1995: 608–12Google Scholar
- 15.Doern GV, Jones RN, Pfaller MA, et al. Haemophilus influenzae and Moraxella catarrhalis from patients with community-acquired respiratory tract infections: antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). Antimicrob Agents Chemother 1999; 43: 385–9PubMedGoogle Scholar
- 19.McPhee SJ, Schroeder SA. General approach to the patient. In: Tierney LM, McPhee SJ, Papadakis MA, editors. Current medical diagnosis & treatment. 36th ed. Stamford (CT): Appleton Publishers, 1997: 1–2Google Scholar
- 20.Woods GL, Washington JA. The clinician and the microbiology laboratory. In: Mandell GL, Douglas Jr RG, Bennett JE, editors. Principles and practice of infectious diseases. 4th ed. New York: Churchill Livingstone, 1995: 169–99Google Scholar
- 21.National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial disk susceptibility tests. 5th ed; approved standard. NCCLS Document M2-A5, 1993, 13(24)Google Scholar
- 22.National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility tests. 5th ed; approved standard. NCCLS Document M2-A5, 1993, 13(24)Google Scholar
- 27.Doern GV, Brueggemann A, Holley HP, et al. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 and 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother 1996; 40: 1208–13PubMedGoogle Scholar